TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05729061

Intervention type: DEVICE
Group type: OTHER
Intervention: Ankle-Foot Orthosis
Description: Commercially available ankle-foot orthosis devices
Study: NCT05605301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral 2-Deoxy-D-Glucose (2DG)
Description: 2DG will be formulated as an solid dosage form and administered orally.
Study: NCT04977245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: Eight MBSR sessions of 1.5 hours per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided Mindfulness eCourse
Description: Six weeks of a mindfulness ecourse, and two weeks of coping skills training led by a licensed neuropsychologist
Study: NCT06559774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hastiin Bidziil
Description: Common Elements Treatment Approach (CETA) modified for cultural and gendered specific delivery for maximum community impact

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control condition - vehicle maintenance
Description: Control condition was selected by the Community Research Council and includes five sessions on basic vehicle maintenance such as changing tire, checking fluid levels, and winterizing vehicles.
Study: NCT05095532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mesenchymal stem cells
Description: MSC transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mesenchymal stem cells
Description: MSC transplantation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of Care
Study: NCT05205473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic nerve block under ultrasound control with a electrostimulator peripheral nerves 12.5 ml 1% lidocaine
Description: Following the ultrasound visualization of the femoral nerve, a insulated injection needle was connected to the nerve stimulator . Under ultrasound visualization guidance, the needle of the electronic nerve stimulator was positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve, and a positive muscular response . Subsequently, the introduction of LA solution was initiated (12.5 ml 1% lidocaine).If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sciatic nerve blockade under ultrasound control without a peripheral nerve stimulator 12.5 ml 1% lidocaine
Description: Under ultrasound visualization guidance, the needle owas positioned at the sciatic nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (12.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a femoral nerve block is performed.
Study: NCT05599776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart ring assisted physiotherapeutic intervention
Description: the effect of a smart ring (Oura), a wearable activity tracker assisted physiotherapeutic intervention on the risk of poor outcome measured on patient reported post-operative outcome (Oxford Knee Score) 12 months after a primary total knee replacement.
Study: NCT04760002

Intervention type: DEVICE
Intervention: NightOwl
Description: The NightOwl consists of a small sensor device which is placed on the fingertip and a smartphone app that is connected to an encrypted cloud-based analytics platform within the European Union, the NightOwl software. It is self-applied by attaching the sensor to the fingertip by means of an adhesive patch. The NightOwl sensor acquires accelerometer data and reflectancebased photoplethysmography (PPG) from which it derives actigraphy (sleep/wake behavior), SpO2, peripheral artery tone (PAT) and pulse rate, among other features. A PAT analysis derives changes in caliber of arteries elicited by alterations in the contractile activity of vascular smooth muscle and are referred to as changes in arterial tone. The end state of the apnea-hypopnea events are associated with sympathetic activation.
Study: NCT05129033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone tablet
Description: Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itraconazole
Description: Anti-fungal medication to reduce fugal load.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Anti-IgE monoclonal antibody, used for high IgE allergic disease.
Study: NCT05621525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBP-398
Description: BBP-398 (formerly known as IACS-15509) is a potent, selective, orally active allosteric inhibitor of SHP2, a tyrosine phosphatase that plays a key role in the RTK -MAPK signal transduction pathway. Key components of the MAPK pathway include the small GTPase RAS, the serine/threonine-protein kinase RAF, mitogen-activated protein kinase (MEK) and ERK. In cells, SHP2 binds to phosphorylated tyrosine residues in the intracellular domain of RTKs such as the EGFR, leading to activation of the downstream MAPK signaling pathway.
Study: NCT06023836

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Patients in this group received three sessions of ESWT (MASTERPLUS MP 200 ENERGY 2 trademarked ESWT device) at an energy density of 2 bars and a frequency of 2,000 shocks/min at 12 Hz for three weeks, each session once a week. Each of the five most sensitive and painful points was given 400 pulses in the supine position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Dry needling with Seirin branded 0.6\*50 mm acupuncture needles will be performed for 3 sessions with one week intervals for the trigger point detected by manual palpation in the medial gastrocnemius, lateral gastrocnemius, soleus, flexor digitorum brevis, quadratus plantae, abductor hallucis brevis muscles of the patients in the group.
Study: NCT06100783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Depot-medroxy Progesterone Acetate Injectable Contraceptives
Description: Depot-medroxy progesterone acetate injectable contraceptives

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Depot-medroxy Progesterone Acetate Injectable Contraceptives
Description: Depot-medroxy progesterone acetate injectable contraceptives
Study: NCT04753892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3SM2-G-CRM197 with squalene adjuvant
Description: Immune challenge agent
Study: NCT04421326

Intervention type: OTHER
Intervention: Analysis of the clot
Description: Blood sampling at the site of intracranial occlusion during Mechanical Thrombectomy
Study: NCT06347042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: qigong exercise + routine medical treatment +Anti-inflammatory diet
Description: 1. Qigong exercise is from traditional Chinese medicine exercise . Qigong is system coordinating slow-flowing movement, deep rhythmic breathing, and a calm meditative state of min Frequency of exercise 3 days a week and 60 min a day, including a 15 min warm up, 40 min and 5min cool down.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine medical treatment +Anti-inflammatory diet only
Description: 1. Anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy, free sugar, and ultra-processed food, rich in sugar, hydrogenated fat, and food additives. are some foods with recognized anti-inflammatory potential~2. routine medical treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine medical treatment +Anti-inflammatory diet only
Description: 1. Anti-inflammatory diet is characterized by the exclusion of potential inflammatory foods, such as gluten, dairy, free sugar, and ultra-processed food, rich in sugar, hydrogenated fat, and food additives. are some foods with recognized anti-inflammatory potential~2. routine medical treatment
Study: NCT05637060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Test Drug
Description: One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Drug
Description: One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
Study: NCT05210062

Intervention type: OTHER
Intervention: Iterative exposure to suxamethonium during ECT sessions
Description: The study is divided into 2 phases: phase P and phase E. Phase P: 10 patients to be included in 1 month with a unique dose of suxamethonium during one session of ECT. One blood sample will be taken from patients before their index ECT session. The objective is to evaluate the feasibility of antibody detection relative to the main objective of the study, to ensure the number of patients to include in phase E (analysis in the following month). Depending on the frequency of antibodies detected, particularly IgG4, the number of patients required for phase E will be revised. If no antibodies are detected, the study will be discontinued.~Phase E: 60 patients to be included in 12 months with 5 blood samples: before the first session of ECT (S0), at 2 weeks (S2), at 4 weeks (S4), between 6 - 14 weeks (preferably at S10) and at 6 months (M6). Only first-time patients or those not having been exposed to ECT in the past 10 years will be included in this phase.
Study: NCT05637060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Drug
Description: One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference Drug
Description: One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
Study: NCT06060938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk stratified arm
Description: * Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~* Measurement of height and weight (baseline)~* Complete a mammography (baseline and every 1-4 years according to the risk-group)~* Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)~* Provide a blood sample for analysis of 313 common genetic variants associated with risk of breast cancer (baseline)~* Receive a screening schedule recommendation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: * Complete a questionnaire about family history of breast cancer, lifestyle, reproductive history (baseline)~* Measurement of height and weight (baseline)~* Complete a mammography (baseline and every second year)~* Complete questionnaires about quality of life, breast cancer worry and anxiety (safety measures) (baseline, day 180, 365, and 800)
Study: NCT05740774

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D ultrasound
Description: 3D ultrasound scanning of the resected tongue tumor will be performed. The margin analysis will be made using the 3D ultrasound image.
Study: NCT05396209

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrated Amniotic Membrane Plug
Description: Using Hydrated Amniotic Membrane plug with vitrectomy to try to close refractory macular hole

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM filling
Description: The ILM filling technique - Rossi et al show that ILM filling technique was more efficacious in closing full-thickness macular holes larger than 630μm, in which the free ILM after peeling is plug into the area of the macular hole

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ILM peeling
Description: Peeling with complete removal of the internal limiting membrane within the vascular arch
Study: NCT06384092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Sun Protection Cream
Description: Apply directly on the designated site till absorbed.
Study: NCT05977738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium
Description: Daily Pitavastatin administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium
Description: Daily Pitavastatin administration
Study: NCT06384092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Benchmark Sun Protection Cream
Description: Apply directly on the designated site till absorbed.
Study: NCT05959889

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo tablets for 4 cycles of AC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Patients will receive motelukast 10 mg for 4 cycles of AC.
Study: NCT06542562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided implant placement
Description: The key difference is that in Group 1, the guide is only used for the drilling sequence, while in Group 2 the guide is used for both the drilling and the actual implant placement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided implant placement
Description: The key difference is that in Group 1, the guide is only used for the drilling sequence, while in Group 2 the guide is used for both the drilling and the actual implant placement.
Study: NCT05977738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium
Description: Daily Pitavastatin administration
Study: NCT04740645

Intervention type: OTHER
Intervention: NOCDURNA Cohort
Description: Non intervention

Intervention type: OTHER
Intervention: LUTS Cohort
Description: Non intervention
Study: NCT06514989

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-residue full nutrition formula podwer
Description: The day before the colonoscopy, subjects were given a low-residue full nutrition formula podwer instead of a traditional self-prepared low-residue diet. Subjects were given 6 packs (60g/pack) pre-packaged FNFP and asked to use the FNFP according to individual needs. The 2 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 1 liter taken 3-5 hours before the colonoscopy.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Self-prepared low-residue diet
Description: Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy. The 3 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 2 liter taken 4-6 hours before the colonoscopy.
Study: NCT05615025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia will be maintained by sevoflurane.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthesia will be maintained by propofol.
Study: NCT05350956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO-RA (Herombopag)
Description: During the correction period, subjects will receive a dose of Herombopag starting at 5-7.5mg once daily, orally for 14 days, subject to dosing adjustment (or discontinuation) depending on their platelet response or at the investigator's discretion. In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO-RA (Herombopag) and rhTPO(Recombinant human thrombopoietin)
Description: During the correction period, subjects will receive a combination of Herombopag and rhTPO, Herombopag starting at a recommended dose of 5mg once daily for 14 days. The recombinant human thrombopoietin dose is 300U/kg. bw/day or 15000U/day per person, once daily, for 14 consecutive days (or as determined by the investigator). In the secondary prophylaxis phase, Herombopag 5mg once daily, starting 5 days before antineoplastic therapy and continuing for 10-14 days.
Study: NCT05952752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: giving dexemedetomidine 12 microgram Iv dripping
Description: Patients in the studied groups will receive either or intravenous Dexemedetomidine 12 µg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethsone IV
Description: 4 mg IV dexamethasone
Study: NCT05083364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-C3
Description: ARO-C3 for sc injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-C3
Description: ARO-C3 for sc injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile normal saline (0.9% NaCl) for sc injection
Study: NCT06674863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive a low literacy educational supplement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo a structured interview

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Undergo a structured interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive standard SCP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Receive standard SCP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive a tailored SCP
Study: NCT04515810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use smartphone application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Engage in standard care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05090033

Intervention type: OTHER
Intervention: ofatumumab
Description: There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.

Intervention type: OTHER
Intervention: ofatumumab
Description: There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT05979779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU6
Description: HU6 is being evaluated for its efficacy in improving liver fat content in subjects with Nonalcoholic Steatohepatitis (NASH)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06081244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: 10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: 10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg every 3 weeks (q3w)
Study: NCT05723588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active repetitive transcranial magnetic stimulation
Description: Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation
Description: Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy for smoking cessation
Description: All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: cognitive behavioral therapy for smoking cessation
Description: All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy
Description: All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a rescue method such as nicotine lozenge or nicotine gum.
Study: NCT06351384

Intervention type: DEVICE
Intervention: miRNA detection test
Description: miRNA sequencing based on Next-Generation Sequencing (NGS) technology

Intervention type: DEVICE
Intervention: miRNA detection test
Description: miRNA sequencing based on Next-Generation Sequencing (NGS) technology

Intervention type: DEVICE
Intervention: miRNA detection test
Description: miRNA sequencing based on Next-Generation Sequencing (NGS) technology
Study: NCT05518604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling with goal of modifying eating behaviors
Description: Dietary counseling will occur virtually a minimum of 4x and as desired by participant in the first year postpartum according to a standard protocol

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling with goal of modifying eating behaviors
Description: Dietary counseling will occur virtually a minimum of 4x and as desired by participant in the first year postpartum according to a standard protocol